BioMarin Pharmaceutical Inc. - BMRN Net earnings per one share for the last twelve months

BioMarin Pharmaceutical Inc. (BMRN) - corporate logo

BioMarin Pharmaceutical is expanding its potential through partnerships with clinics and geneticists, accelerating the release of medications. The current EPS YoY TTM trajectory on the GURU.Markets terminal linear chart shows that the indicator level is -103.20. Government preferences and patent protection ensure a monopoly in niche markets, while high-margin innovative drugs create unique opportunities for the therapy of rare genetic pathologies.

BMRN: biomarin.com Net earnings per share for the last 12 months 02/11/2024 - 11/17/2026

BioMarin Pharmaceutical - analytical breakdowns and key metrics (BMRN)

- stock quotes and analyst forecast:
Fundamental company valuation:BMRN - BioMarin Pharmaceutical Inc.
Brand item of BioMarin Corp

The asset's margin of safety is determined by the business's ability to generate excess cash flow. BioMarin Pharmaceutical (BMRN) dominance in the therapy of rare pathologies and its patent protection minimize pricing risks, stabilizing returns. The relative YoY EPS growth over the last 12 months measures the dynamics of net profit per share over four quarters compared to the industry benchmark. This metric classifies the asset as high-tech growth with protected margins.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)